Chapter 7: EU law and policy on pharmaceuticals marketing and post-market control including product liability
Marcus Pilgerstorfer
Category:
Handbook Chapter
Published:
31 Mar 2017
Page Range:
156–196
Collection:
Law 2017
DOI:
https://doi.org/10.4337/9781785364723.00019
Restricted access

Marcus Pilgerstorfer considers how EU regulation and litigation based on EU health law interact in the case of pharmaceuticals, leaving uncertainties in the legal position with potential policy implications. The chapter considers some principal interactions between the EU’s regulatory regime for medicinal products, and its system of civil liability for defective products – focusing on marketing authorisation, labelling and advertising, post-market obligations and the Product Liability Directive.

You are not authenticated to view the full text of this chapter or article.

Access options

Get access to the full article by using one of the access options below.

Other access options

Redeem Token

Institutional Login

Log in with Open Athens, Shibboleth, or your institutional credentials

Login via Institutional Access

Personal login

Log in with your Elgar Online account

Login with your Elgar account
Cover Research Handbook on EU Health Law and Policy
Research Handbook on EU Health Law and Policy
Edited by
Tamara K. Hervey
,
Calum A. Young
, and
Louise E. Bishop
Handbook
Published:
31 Mar 2017
Print ISBN:
9781785364716
eISBN:
9781785364723
DOI:
https://doi.org/10.4337/9781785364723
Pages:
c 640
Collection:
Law 2017
Buy Print